Senores Pharmaceuticals IPO Live
Already have an account? Apply now
Schedule of Senores Pharmaceuticals
| Issue open date | 20 Dec 2024 |
| Issue close date | 24 Dec 2024 |
| UPI mandate deadline | 24 Dec 2024 (5 PM) |
| Allotment finalization | 26 Dec 2024 |
| Refund initiation | 27 Dec 2024 |
| Share credit | 27 Dec 2024 |
| Listing date | 30 Dec 2024 |
| Mandate end date | 08 Jan 2025 |
| Lock-in end date for anchor investors (50%) | 25 Jan 2025 |
| Lock-in end date for anchor investors (remaining) | 26 Mar 2025 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Senores Pharmaceuticals
Senores Pharmaceuticals Limited is a global, research-driven pharmaceutical company specializing in developing and manufacturing complex and specialty products for regulated markets like the US, Canada, and the UK, with a presence in 43 emerging markets. The company focuses on underpenetrated and high-demand molecules, leveraging strong R&D capabilities to deliver critical care injectables, APIs, and diverse dosage forms. Trusted by partners like Prasco LLC, Sun Pharma, and Cipla USA, Senores stands out for quality, innovation, and a robust pipeline of complex pharmaceutical products.
Financials of Senores Pharmaceuticals
Issue size
| Funds Raised in the IPO | Amount |
| Overall | ₹582.11 crores |
| Fresh Issue | ₹500 crores |
| Offer for sale | ₹82.11 crores |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Investment in Havix for facility setup | 107 (35.26%) |
| Repayment of borrowings | 73.48 (24.22%) |
| Havix borrowing repayment | 20.22 (6.66%) |
| Capital requirements | 43.26 (14.26%) |
| SPI & Ratnatris working capital | 59.48 (19.60%) |
Strengths
- Expanding manufacturing for sterile injections.
- Reducing operational debt through funding.
- Strategic fund allocation to subsidiaries.
- Focus on growth through acquisitions.
Risks
- High dependence on borrowed funds.
- Regulatory hurdles in manufacturing.
- Market volatility impacts growth plans.
- Challenges in fund utilization across subsidiaries.
Subscription Figures for Senores Pharmaceuticals
Subscription numbers as of 5:00 PM on 20 Dec 2024:
| Category | Reserved (lakhs) | Applied (lakhs) | Subscription (X times) |
|---|---|---|---|
| Institutional | 45.93 | 0.28 | 0.01x |
| HNI (₹2L+) | 23.20 | 38.69 | 1.67x |
| Retail (upto ₹2L) | 15.47 | 111.12 | 7.19x |
| Employees | 0.75 | 1.41 | 1.88x |
| Total | 85.35 | 151.51 | 1.78x |